InsidersTradesSigma
Follow the Merck & Co., Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Merck & Co., Inc. has recorded 248 public disclosures. Market capitalisation: €327.9bn. The latest transaction was disclosed on 13 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Oosthuizen Johannes Jacobus. Every trade is openly available.
248
Insider Decl.
n/a
Thresholds
€2m
3 ops.
Buy Volume
€50m
43 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Merck & Co., Inc. Buy (bullish), based on 26 analysts. Average price target: US$136.85.
44Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 8,367 of 29,062 companies
62.0
score / 100
Value53
Quality71
FCF yld3.4%
Earn yld5.0%
EV/EBITDA14.7x
ROE7.0%
Gross mgn75%
Net mgn28%
Debt/EBITDA1.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 13 August 2026
Declarations248 total
10,000 shares@ US$135.00CommonSEC144:0001950047-26-008057
10,000 shares@ US$135.000.0004% mcap5.6% of flowCommon StockSEC:0000310158-26-000223:0
41,494 shares@ US$117.890.0015% mcap12.4% of flowCommon StockSEC:0000310158-26-000221:0
13,433 shares@ US$84.710.0003% mcap2.9% of flowCommon StockSEC:0000310158-26-000221:1
80,315 shares@ US$133.45570.0033% mcap27.2% of flowCommon StockSEC:0000310158-26-000221:2
11,699 shares@ US$131.63450.0005% mcap22.9% of flowCommonSEC144:0001950047-26-008012
80,315 shares@ US$133.45570.0033% mcap100.0% of flowCommonSEC144:0001950047-26-008008
7,410 shares@ US$131.33130.0003% mcap2.8% of flowCommon StockSEC:0000310158-26-000219:1
5,427 shares@ US$132.34960.0002% mcap2.1% of flowCommon StockSEC:0000310158-26-000219:2
11,099 shares@ US$131.61280.0005% mcap4.2% of flowCommon StockSEC:0000310158-26-000219:3
600 shares@ US$132.03670.0000% mcap0.2% of flowCommon StockSEC:0000310158-26-000219:4
20,784 shares@ US$130.43450.0009% mcap7.8% of flowCommon StockSEC:0000310158-26-000219:0
12,837 shares@ US$131.76180.0005% mcap32.6% of flowCommonSEC144:0001950047-26-007942
20,784 shares@ US$130.43450.0009% mcap77.5% of flowCommonSEC144:0001950047-26-007905
805 shares@ US$131.02160.0000% mcap0.4% of flowCommon StockSEC:0000310158-26-000217:0
4,945 shares@ US$130.23120.0002% mcap2.2% of flowCommon StockSEC:0000310158-26-000217:1
300 shares@ US$131.02330.0000% mcap0.1% of flowCommon StockSEC:0000310158-26-000217:2
15,000 shares@ US$131.000.0006% mcap8.7% of flowCommon StockSEC:0000310158-26-000213:0
6,311 shares@ US$73.730.0001% mcap11.8% of flowCommon StockSEC:0000310158-26-000215:0
6,311 shares@ US$128.71790.0003% mcap20.6% of flowCommon StockSEC:0000310158-26-000215:1
9,709 shares@ US$87.100.0003% mcap21.4% of flowCommon StockSEC:0000310158-26-000215:2
9,709 shares@ US$128.71790.0004% mcap31.7% of flowCommon StockSEC:0000310158-26-000215:3
2,686 shares@ US$84.710.0001% mcap5.8% of flowCommon StockSEC:0000310158-26-000215:4
2,686 shares@ US$128.71790.0001% mcap8.8% of flowCommon StockSEC:0000310158-26-000215:5
4,600 shares@ US$77.620.0001% mcap2.0% of flowCommon StockSEC:0000310158-26-000214:0
25 of 248 declarations
关于 Merck & Co., Inc.
默沙东公司（Merck & Co., Inc.）是一家领先的美国制药公司，在纽约证券交易所上市，股票代码为MRK，总部位于美国新泽西州拉威。对于讲法语的投资者而言，默沙东最好被理解为一个全球医疗保健平台，而非单一产品公司：它业务涵盖处方药、疫苗、生物疗法和动物保健。在美国和加拿大以外，该公司使用MSD品牌。默沙东报告称，2025年约有75,000名员工，营收达65.0 billion美元，这突显了其作为全球医疗保健领域主要防御性大盘股之一的规模。（[merck.com](https://www.merck.com/media/company-fact-sheet/)) 默沙东成立于1891年，通过科学深度、商业执行和持续的研发投入，在全球制药领域建立了长期地位。其运营结构围绕三大核心业务：制药、疫苗和动物保健。该公司2025年的研发支出达到15.8 billion美元，这反映了在肿瘤学、传染病、心血管代谢护理和其他治疗领域维持产品线的资本密集度。（[merck.com](https://www.merck.com/media/company-fact-sheet/)) 从竞争角度来看，默沙东在肿瘤学和传染病预防方面尤其强大，同时在动物保健领域也占据重要地位。其最知名的特许经营产品仍然是KEYTRUDA，这一免疫肿瘤学基石持续支撑着公司的盈利能力。公司还强调了WINREVAIR的上市势头及其动物保健业务的韧性，这些都是2024年增长的重要贡献者。这种组合为默沙东带来了盈利质量和产品线选择权，尽管未来的业绩仍高度依赖专利周期、临床成功和上市执行。（[merck.com](https://www.merck.com/stories/our-q4-and-full-year-2024-financial-results/)) 默沙东的地理足迹广泛而多样化。2025年，美国贡献了36.5 billion美元的收入，其次是欧洲、中东和非洲，为14.6 billion美元；拉丁美洲为3.4 billion美元；除日本/中国以外的亚太地区为3.0 billion美元；日本为2.7 billion美元；中国为1.9 billion美元；其他地区为2.9 billion美元。这种分布表明该公司在国内市场拥有强大的影响力，同时在国际市场也实现了可观的盈利。（[merck.com](https://www.merck.com/media/company-fact-sheet/)) 近期发展强化了以创新为主导的增长投资案例。2025年6月，FDA批准了ENFLONSIA，这是默沙东用于进入首个RSV季节的新生儿和婴儿的RSV预防性单克隆抗体，为产品组合增加了新的呼吸道资产。公司还报告了enlicitide decanoate（一种用于高脂血症的口服PCSK9抑制剂）的积极3期数据，并宣布以约9.2 billion美元收购Cidara Therapeutics的协议，以进一步多元化进入后期抗病毒资产。总而言之，这些举措表明默沙东正在积极更新其增长产品线，同时在美国纽约证券交易所捍卫其核心特许经营权。（[merck.com](https://www.merck.com/news/u-s-fda-approves-mercks-enflonsia-clesrovimab-cfor-for-prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease-in-infants-born-during-or-entering-their-fir/))
